CD8+ T cells infiltrate the heart concurrently with DR-induced cardiac pathology and systemic inflammation. Credit: Nature Cardiovascular Research (2024). DOI: 10.1038/s44161-024-00507-y There’s still much to learn about how doxorubicin, a 50-year-old chemotherapy drug, causes its most concerning side effects. While responsible for saving many lives, this treatment sometimes causes cardiac damage that stiffens the heart and puts a subset of patients at risk for future heart failure. To better understand and potentially control such complications, Tufts University School of Medicine and Tufts Graduate School of Biomedical Sciences researchers have isolated the immune cells that become overactive when patients take doxorubicin. Read More
No comments:
Post a Comment